Zinc Oxide Nanoparticles Trigger Autophagy in the Human Multiple Myeloma Cell Line RPMI8226: an In Vitro Study

Li, Zonghong; Yin, Xuewei; Lyu, Chunyi; Wang, Jingyi; Liu, Kui; Cui, Shangbin; Ding, Shumin; Wang, Yingying; Guo, Dadong; Xu, Ruirong

doi:10.1007/s12011-023-03737-6

Cited by 2 publications

(1 citation statement)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The flexible preparation options, excellent biocompatibility, adjustable size, and unique physicochemical properties make the inorganic nanomaterials popular application in imaging and drug delivery in cancer therapy ( Wang et al, 2016 ). Furthermore, some inorganic nanoparticles can self-made medicine to kill cancer cells ( Adamo et al, 2023 ; Li Z. et al, 2023 ). Inorganic nanocarriers are prepared by inorganic materials such as silica and metal materials, etc.…”

Section: The Application Of Nanocarriers-mediated Drug Deliverymentioning

confidence: 99%

The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment

Liu,

Yu,

Chen

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Hematologic malignancies (HMs), also referred to as hematological or blood cancers, pose significant threats to patients as they impact the blood, bone marrow, and lymphatic system. Despite significant clinical strategies using chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapy, or immunotherapy, the five-year overall survival of patients with HMs is still low. Fortunately, recent studies demonstrate that the nanodrug delivery system holds the potential to address these challenges and foster effective anti-HMs with precise treatment. In particular, cell membrane camouflaged nanodrug offers enhanced drug targeting, reduced toxicity and side effects, and/or improved immune response to HMs. This review firstly introduces the merits and demerits of clinical strategies in HMs treatment, and then summarizes the types, advantages, and disadvantages of current nanocarriers helping drug delivery in HMs treatment. Furthermore, the types, functions, and mechanisms of cell membrane fragments that help nanodrugs specifically targeted to and accumulate in HM lesions are introduced in detail. Finally, suggestions are given about their clinical translation and future designs on the surface of nanodrugs with multiple functions to improve therapeutic efficiency for cancers.

show abstract

Section: The Application Of Nanocarriers-mediated Drug Deliverymentioning

confidence: 99%